Phase 2b

Centrexion Therapeutics Announces Highly Statistically Significant Topline Results from Phase 2b Study of CNTX-4975 in Patients with Knee Osteoarthritis Pain

Boston – December 13, 2016 – Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest…